The global Infectious Disease Diagnostics Market size was estimated at USD 32.2 Bn in 2021, growing at a CAGR of 6.9% during the forecast period 2021-2027. Infectious disease diagnostics are the procedures for the identification and characterization of the causative agent of an infectious disease with the aid of diagnostic tools. These diagnostics provide crucial information for making the right medical decisions. Infectious diseases are caused by various micro-organisms such as viruses, bacteria, fungi, and parasites. Infectious diseases are transmitted from person to person through either indirect or direct contact. Infectious diseases such as bacterial infections, fungal infections, and viral infections such as respiratory diseases, HPV, HIV, measles, malaria, dengue, cholera, and hepatitis B and C are gradually spreading worldwide. This market can be based solely on clinical presentation or more rigorous diagnostic tests, such as microscopy, biochemical screens, culturing of an infectious agent, and molecular methods. Geographically, the global infectious disease diagnostics market is in the flourishing stage, with the development of novel technologies by various players in the market. The increasing prevalence of the deadly infectious disease will drive the growth of the global infectious disease diagnostics market over the forecast period. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Innovation of technologically advanced devices with quick results, ease of usage, accuracy, and low cost are expected to boost the global infectious disease diagnostics market. For instance, in 2013, Abbott Molecular introduced a new range of real-time assays for hepatitis B virus, and hepatitis C virus infections on its m2000 platform. The majority of companies are making efforts to develop and commercialize cost-effective tools for infectious disease diagnostics. Nowadays, the gold standard tests are available for sexually transmitted disease and bacterial infection diagnosis, and these tests are expected to replace by molecular techniques in the future.